Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.52
  • Today's Change-0.17 / -2.99%
  • Shares traded6.32m
  • 1 Year change-22.91%
  • Beta0.8179
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5,9917,0124,768
Total Receivables, Net1,4101,3121,866
Total Inventory778713691
Prepaid expenses106505281
Other current assets, total907209185
Total current assets9,1939,7517,791
Property, plant & equipment, net5,1544,5023,828
Goodwill, net4,1994,1403,844
Intangibles, net1,5541,5781,849
Long term investments3,1331,3801,321
Note receivable - long term----0
Other long term assets117----
Total assets23,62522,00919,213
LIABILITIES
Accounts payable212250230
Accrued expenses994743643
Notes payable/short-term debt000
Current portion long-term debt/capital leases2,121425161
Other current liabilities, total400426385
Total current liabilities3,7281,8441,420
Total long term debt2,7174,0932,468
Total debt4,8384,5192,629
Deferred income tax251280264
Minority interest2,4802,4382,430
Other liabilities, total417429402
Total liabilities9,5919,0836,985
SHAREHOLDERS EQUITY
Common stock0.150.150.16
Additional paid-in capital3,5173,6934,152
Retained earnings (accumulated deficit)10,8249,3277,873
Treasury stock - common(236)(236)--
Unrealized gain (loss)(152)(36)98
Other equity, total79176104
Total equity14,03412,92612,227
Total liabilities & shareholders' equity23,62522,00919,213
Total common shares outstanding2,3992,3992,522
Treasury shares - common primary issue40400
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.